Shionogi Seeks Approval for COVID-19 Prophylaxis Drug in Japan

Shionogi & Co ( (JP:4507) ) just unveiled an update.

Shionogi & Co., Ltd. has submitted a supplemental New Drug Application in Japan for its oral antiviral drug, ensitrelvir, intended for post-exposure prophylaxis of COVID-19. If approved, it will be the first oral option for this purpose, enhancing Shionogi’s position in the antiviral market. The application is supported by positive results from a Phase 3 study, which demonstrated the drug’s efficacy in preventing COVID-19 in exposed individuals. This development could significantly impact COVID-19 management, offering a new preventive measure amid challenges with vaccination rates and emerging variants.

More about Shionogi & Co

Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, specializing in the development of drugs and treatments, particularly focusing on antiviral medications. The company has been actively involved in creating solutions for COVID-19, with a strong emphasis on antiviral therapies.

YTD Price Performance: 35.66%

Average Trading Volume: 276

Technical Sentiment Signal: Sell

Current Market Cap: $13.65B

Find detailed analytics on 4507 stock on TipRanks’ Stock Analysis page.